文献速递白血病

单细胞图谱识别慢性髓性白血病原发伊马替尼耐药的预处理特征

A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia.
PubMed 文献 · Blood · 2023-01-01

该研究利用单细胞RNA测序在伊马替尼治疗前的骨髓中识别出8个与疗效(主要分子学反应或极端耐药至急变期转化)显著相关的特征,机器学习模型基于白血病干细胞和自然杀伤细胞基因表达谱预测伊马替尼反应准确率超过80%,且预测急变期无假阳性。红系定向调控子(TAL1/KLF1/GATA1)是主要分子学反应患者白血病干细胞的标志,并与红系祖细胞体内扩增相关(P < .05),红系祖细胞对酪氨酸激酶抑制剂敏感性显著高于髓系祖细胞(P < .001)。

要点

  • 治疗前骨髓单细胞RNA测序识别8个与伊马替尼敏感性或极端耐药显著相关的特征。
  • 机器学习模型基于白血病干细胞和自然杀伤细胞表达谱预测伊马替尼反应准确率超过80%,预测急变期无假阳性。
  • 红系祖细胞对酪氨酸激酶抑制剂敏感性显著高于髓系祖细胞(P < .001)。

核心结论

  • 治疗前白血病干细胞和自然杀伤细胞基因表达特征可预测伊马替尼反应,准确率超过80%且预测急变期无假阳性。
  • 红系定向调控子是主要分子学反应患者白血病干细胞的标志,并与红系祖细胞扩增相关。
  • 这些白血病干细胞特征随耐药进展而丢失,MYC和IRF1驱动的炎症调控子在进展至转化的患者中明显。

研究设计与样本

  • 研究采用单细胞RNA测序分析伊马替尼治疗前骨髓样本,识别与主要分子学反应或极端耐药至急变期转化相关的特征。
  • 研究运用机器学习方法建立基于白血病干细胞和自然杀伤细胞基因表达谱的预测模型。
  • 研究开发抗体面板以验证单细胞RNA测序发现。

主要发现

  • 治疗前骨髓中识别出8个统计显著特征,与伊马替尼敏感性(主要分子学反应)或极端耐药(最终急变期转化)相关。
  • 机器学习模型预测伊马替尼反应准确率超过80%,预测急变期无假阳性。
  • 红系定向调控子(TAL1/KLF1/GATA1)是主要分子学反应患者白血病干细胞的标志,与红系祖细胞体内扩增相关(P < .05),体外红系对髓系偏倚为2至10倍(A组6.3倍 vs C组1.09倍)。
  • 红系祖细胞对酪氨酸激酶抑制剂敏感性显著高于髓系祖细胞(P < .001)。
  • 主要分子学反应患者中正常罕见的高功能适应性样自然杀伤细胞亚群扩增56倍(P < .01),该扩增随耐药进展而减少,而 destined for 急变期患者积累抑制性NKG2A+自然杀伤细胞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary resistance to tyrosine kinase inhibitors (TKIs) is a significant barrier to optimal outcomes in chronic myeloid leukemia (CML), but factors contributing to response heterogeneity remain unclear. Using single-cell RNA (scRNA) sequencing, we identified 8 statistically significant features in pretreatment bone marrow, which correlated with either sensitivity (major molecular response or MMR) or extreme resistance to imatinib (eventual blast crisis [BC] transformation). Employing machine-learning, we identified leukemic stem cell (LSC) and natural killer (NK) cell gene expression profiles predicting imatinib response with >80% accuracy, including no false positives for predicting BC. A canonical erythroid-specifying (TAL1/KLF1/GATA1) regulon was a hallmark of LSCs from patients with MMR and was associated with erythroid progenitor [ERP] expansion in vivo (P < .05), and a 2- to 10-fold (6.3-fold in group A vs 1.09-fold in group C) erythroid over myeloid bias in vitro. Notably, ERPs demonstrated exquisite TKI sensitivity compared with myeloid progenitors (P < .001). These LSC features were lost with progressive resistance, and MYC- and IRF1-driven inflammatory regulons were evident in patients who progressed to transformation. Patients with MMR also exhibited a 56-fold expansion (P < .01) of a normally rare subset of hyperfunctional adaptive-like NK cells, which diminished with progressive resistance, whereas patients destined for BC accumulated inhibitory NKG2A+ NK cells favoring NK cell tolerance. Finally, we developed antibody panels to validate our scRNA-seq findings. These panels may be useful for prospective studies of primary resistance, and in assessing the contribution of predetermined vs acquired factors in TKI response heterogeneity.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Krishnan V, Schmidt F, Nawaz Z, et al. A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia. Blood. 2023. PMID: 36857629. doi:10.1182/blood.2022017295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。